Literature DB >> 16881935

Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study.

S M Boekholdt1, M S Sandhu, N J Wareham, R Luben, P H Reitsma, K-T Khaw.   

Abstract

BACKGROUND: The factor (F) XIII Val34Leu variant has been implicated in coronary artery disease (CAD). In vitro evidence suggests an interaction between this variant and fibrinogen concentrations in determining thrombus structure.
OBJECTIVES: To test whether this interaction is relevant in influencing coronary risk in apparently healthy individuals.
METHODS: In an 8-year prospective population study of 25 663 men and women, we compared 898 apparently healthy men and women developing incident CAD with 1580 matched controls.
RESULTS: Overall, the FXIII Val34Leu variant was not associated with the risk of future CAD. However, a significant interaction existed between the Val34Leu variant and fibrinogen levels for the risk of future CAD (P = 0.004). Among people in the lowest tertile of fibrinogen concentrations, LeuLeu carriers had an odds ratio (OR) of 2.88 (95% confidence interval; CI 1.24-6.74) compared to wild-type individuals (P for linearity = 0.003). By contrast, among those in the highest fibrinogen tertile, LeuLeu carriers were had a lower risk than wild-type individuals (OR 0.47, 95% CI 0.18-1.17, P for linearity = 0.1).
CONCLUSIONS: Our results suggest that a significant gene-covariate interaction exists between the FXIII Val34Leu variant and fibrinogen levels. Relationships between genotype and disease risk may be altered by biological covariates. Simplistic paradigms of gene or biomarker associations are unlikely to fully characterize disease risk in populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16881935     DOI: 10.1111/j.1538-7836.2006.02154.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

Review 1.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

Review 2.  Molecular mechanisms affecting fibrin structure and stability.

Authors:  Susan T Lord
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03       Impact factor: 8.311

3.  Risk for early pregnancy loss by factor XIII Val34Leu: the impact of fibrinogen concentration.

Authors:  Astrid Dossenbach-Glaninger; Mick van Trotsenburg; Christian Oberkanins; Johanna Atamaniuk
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

4.  EPIC-Heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries.

Authors:  John Danesh; Rodolfo Saracci; Göran Berglund; Edith Feskens; Kim Overvad; Salvatore Panico; Simon Thompson; Agnès Fournier; Françoise Clavel-Chapelon; Marianne Canonico; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Tobias Pischon; Cornelia Weikert; Anja Olsen; Anne Tjønneland; Søren Paaske Johnsen; Majken Karoline Jensen; Jose R Quirós; Carlos Alberto Gonzalez Svatetz; Maria-José Sánchez Pérez; Nerea Larrañaga; Carmen Navarro Sanchez; Concepción Moreno Iribas; Sheila Bingham; Kay-Tee Khaw; Nick Wareham; Timothy Key; Andrew Roddam; Antonia Trichopoulou; Vassiliki Benetou; Dimitrios Trichopoulos; Giovanna Masala; Sabina Sieri; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; W M Monique Verschuren; H Bas Bueno-de-Mesquita; Diederick E Grobbee; Yvonne T van der Schouw; Olle Melander; Göran Hallmans; Patrik Wennberg; Eiliv Lund; Merethe Kumle; Guri Skeie; Pietro Ferrari; Nadia Slimani; Teresa Norat; Elio Riboli
Journal:  Eur J Epidemiol       Date:  2007-02-13       Impact factor: 12.434

Review 5.  Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.

Authors:  Vassilios P Memtsas; Deepa R J Arachchillage; Diana A Gorog
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.